The study involved adults with type 2 diabetes and cardiovascular risk, who were randomized to receive tirzepatide (5 mg, 10 mg, or 15 mg) or insulin glargine (100 U/mL) over a treatment period of up to 104 weeks
Several errors in handling tirzepatide vials can compromise medication safety and efficacy
While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients
This may lead to: More regular periods Improved ovulation Better hormone balance Increased fertility Some women with PCOS who rarely had periods before treatment may suddenly begin cycling more consistently
A Cambridge, Massachusetts man, who allegedly communicated directly with a supplier in China to obtain controlled substances and fentanyl precursor chemicals, was sentenced to 13 years in prison in connection with a large-scale counterfeit pill manufacturing operation
"Once-Weekly Tirzepatide for Treatment of Type 2 Diabetes." Published in NEJM, Accessed on November 7, 2023 at FDA Press Announcement